Atezolizumab

Generic Name: Atezolizumab

Brand Names: Tecentriq

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1380723-44-3

Unique Ingredient Identifier: 52CMI0WC3Y

Background: Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.

Indication: Atezolizumab has approved indications for the following conditions:

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Hepatocellular Carcinoma (HCC)

Melanoma

Alveolar Soft Part Sarcoma (ASPS)

Associated Conditions: Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma

Associated Therapies: -

Clinical Trials

MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma

Phase 1

Active, not recruiting

Conditions: Sarcoma,Soft Tissue

Interventions: Drug: Cobimetinib
Drug: Atezolizumab

First Posted Date: 2020-01-03

Last Posted Date: 2024-07-08

Lead Sponsor: Centre Leon Berard

Target Recruit Count: 320

Registration Number: NCT04216953

Locations: 🇫🇷
Hôpital de la Timone, Marseille, France
🇫🇷
Institut Gustave Roussy, Villejuif, France
🇫🇷
Institut Curie, Paris, France

and more 3 locations

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Stage I Lung Cancer AJCC v8
Lung Non-Small Cell Carcinoma
Stage II Lung Cancer AJCC v8

Interventions: Procedure: Biospecimen Collection
Drug: Atezolizumab
Other: Fludeoxyglucose F-18
Procedure: Computed Tomography
Procedure: Positron Emission Tomography
Other: Questionnaire Administration
Other: Quality-of-Life Assessment
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2020-01-02

Last Posted Date: 2024-11-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 480

Registration Number: NCT04214262

Locations: 🇺🇸
Springfield Memorial Hospital, Springfield, Illinois, United States
🇺🇸
Marshfield Medical Center - Minocqua, Minocqua, Wisconsin, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 388 locations

Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies

Phase 1

Terminated

Conditions: Gastrointestinal Cancer

Interventions: Drug: Cobimetinib
Drug: Hydroxychloroquine
Drug: Atezolizumab

First Posted Date: 2020-01-02

Last Posted Date: 2024-12-18

Lead Sponsor: Columbia University

Target Recruit Count: 27

Registration Number: NCT04214418

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
🇺🇸
Brown University, Providence, Rhode Island, United States

BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab

Phase 1

Active, not recruiting

Conditions: Tumor, Solid

Interventions: Drug: BDB001
Drug: Atezolizumab

First Posted Date: 2019-12-12

Last Posted Date: 2024-04-22

Lead Sponsor: Eikon Therapeutics

Target Recruit Count: 40

Registration Number: NCT04196530

Locations: 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸
Angeles Clinic, Los Angeles, California, United States
🇺🇸
NEXT Oncology, San Antonio, Texas, United States

and more 2 locations

A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)

Phase 3

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Atezolizumab
Drug: Placebo
Drug: Bevacizumab
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Carboplatin

First Posted Date: 2019-12-11

Last Posted Date: 2024-07-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 305

Registration Number: NCT04194203

Locations: 🇨🇳
Guangxi Cancer Hospital of Guangxi Medical University, Nanning City, China
🇨🇳
First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, China
🇨🇳
Nan Tong Tumor Hospital, Nantong City, China

and more 20 locations

A MolEcularly Guided Anti-Cancer Drug Off-Label Trial

Phase 2

Active, not recruiting

Conditions: Solid Tumor

Interventions: Drug: Everolimus
Drug: Atezolizumab
Drug: Niraparib
Drug: Cobimetinib

First Posted Date: 2019-12-04

Last Posted Date: 2024-08-22

Lead Sponsor: Uppsala University Hospital

Target Recruit Count: 167

Registration Number: NCT04185831

Locations: 🇸🇪
Skane University Hospital, Lund, Sweden
🇸🇪
Uppsala University Hospital, Uppsala, Sweden
🇸🇪
Sahlgrenska University Hospital, Gothenburg, Sweden

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Phase 1

Recruiting

Conditions: Advanced Solid Tumors
Kirsten Rat Sarcoma (KRAS) pG12C Mutation

Interventions: Drug: Sotorasib
Drug: RMC-4630
Drug: Afatinib
Drug: MVASI® (bevacizumab-awwb)
Drug: Atezolizumab
Drug: TNO155
Drug: BI 1701963
Drug: AMG 404
Drug: Trametinib
Drug: Pembrolizumab
Drug: Palbociclib
Drug: Everolimus
Drug: IV Chemotherapy (Regimen 1)
Drug: Carboplatin, pemetrexed, docetaxel, paclitaxel
Drug: Panitumumab
Drug: IV Chemotherapy (Regimen 2)

First Posted Date: 2019-12-04

Last Posted Date: 2024-11-28

Lead Sponsor: Amgen

Target Recruit Count: 1200

Registration Number: NCT04185883

Locations: 🇺🇸
Henry Ford Cancer Detroit (Brigitte Harris Cancer Pavilion), Detroit, Michigan, United States
🇺🇸
Arizona Oncology Associates Professional Corporation, Tucson, Arizona, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States

and more 87 locations

Atezolizumab Plus Bevacizumab With HCC and HBV Infection

Not Applicable

Active, not recruiting

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Atezolizumab
Drug: Bevacizumab

First Posted Date: 2019-11-27

Last Posted Date: 2024-07-05

Lead Sponsor: National Health Research Institutes, Taiwan

Target Recruit Count: 51

Registration Number: NCT04180072

Locations: 🇨🇳
Mackay Memorial Hospital, Taipei, Taiwan
🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan

and more 4 locations

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Phase 3

Completed

Conditions: Triple-Negative Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Atezolizumab
Drug: Ipatasertib
Drug: Placebo for Atezolizumab
Drug: Placebo for Ipatasertib

First Posted Date: 2019-11-26

Last Posted Date: 2024-03-27

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 242

Registration Number: NCT04177108

Locations: 🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States
🇨🇦
McGill University; Glen Site; Oncology, Montreal, Quebec, Canada
🇨🇦
Royal Victoria Hospital, Barrie, Ontario, Canada

and more 178 locations

WaKING: Wnt and checKpoint INhibition in Gastric Cancer

Phase 1

Active, not recruiting

Conditions: Metastatic Esophageal Cancer
Metastatic Gastric Cancer

Interventions: Drug: Atezolizumab

First Posted Date: 2019-11-18

Last Posted Date: 2024-08-02

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 52

Registration Number: NCT04166721

Locations: 🇬🇧
The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy